Efficacy and safety of valsartan in children aged 1-5 years with hypertension, with or without chronic kidney disease: A 6-week randomised, multicentre, double-blind study followed by open-label phase
2 September 2019 (14:00 - 18:00)
Organised by:
Abstract
Slides
About the speaker
Novartis, Hyderabad (India)
14 More presentations in this session
Access the full session
The Event
ESC Congress 2019
2 September 2019
14:00 CET
You may be interested in
Congress Session
